Drug
Ak119
Ak119: highest development phase Phase 1/2, developed by Akeso. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Akeso
Trials
| Drug | Phase | Indication |
|---|---|---|
| AK119 NCT05846867 | Phase 1/2 | Colorectal Cancer |
| AK119 NCT05689853 | Phase 1/2 | Solid Tumor, Adult |
| AK119 NCT05173792 | Phase 1 | Solid Tumor |
Latest
No recent events.
Follow Ak119 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.